{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:59:43Z","timestamp":1761058783640},"reference-count":33,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2002,2,1]],"date-time":"2002-02-01T00:00:00Z","timestamp":1012521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2002,2]]},"DOI":"10.1053\/ajkd.2002.30566","type":"journal-article","created":{"date-parts":[[2008,3,21]],"date-time":"2008-03-21T01:11:42Z","timestamp":1206061902000},"page":"426-432","source":"Crossref","is-referenced-by-count":14,"title":["Just the FAQs: Frequently asked questions about iron and anemia in patients with chronic kidney disease"],"prefix":"10.1053","volume":"39","author":[{"given":"David B.","family":"Van Wyck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Bailie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Aronoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1053\/ajkd.2002.30566_bib1","first-page":"S1","article-title":"2000 Annual Report: ESRD Clinical Performance Measures Project","volume":"37","author":"Health Care Financing Administration","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.30566_bib2","first-page":"335","article-title":"Trends in erythropoietin therapy in the U.S. dialysis population:1995 to 1998","volume":"20","author":"Kimmel","year":"2000","journal-title":"Semin Nephrol"},{"key":"10.1053\/ajkd.2002.30566_bib3","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/ajkd.2001.21293","article-title":"Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American Clinical Trial","volume":"37","author":"Charytan","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.30566_bib4","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1093\/ndt\/13.4.847","article-title":"What is the most appropriate strategy to monitor functional iron deficiency in the dialysed patient on rHuEPO therapy? Merits of percentage hypochromic red cells as a marker of functional iron deficiency","volume":"13","author":"Macdougall","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/ajkd.2002.30566_bib5","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/00041552-199711000-00012","article-title":"Laboratory diagnosis of anaemia in dialysis patients: Use of common laboratory tests","volume":"6","author":"Sunder-Plassmann","year":"1997","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1053\/ajkd.2002.30566_bib6","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S0272-6386(97)90104-9","article-title":"Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO","volume":"30","author":"Mittman","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.30566_bib7","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1046\/j.1523-1755.1999.00627.x","article-title":"Factors determining the percentage of hypochromic red blood cells in hemodialysis patients","volume":"56","author":"Bovy","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2002.30566_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/BF02550560","article-title":"The importance of serum transferrin receptor level in the diagnosis of functional iron deficiency due to recombinant human erythropoietin treatment in haemodialysis patients","volume":"30","author":"Tonbul","year":"1998","journal-title":"Int Urol Nephrol"},{"key":"10.1053\/ajkd.2002.30566_bib9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0272-6386(99)70259-3","article-title":"Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients","volume":"33","author":"Gunnell","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.30566_bib10","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1046\/j.1523-1755.1998.00084.x","article-title":"Role of cytokines in the response to erythropoietin in hemodialysis patients","volume":"54","author":"Goicoechea","year":"1998","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2002.30566_bib11","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1681\/ASN.V95869","article-title":"EPIBACDIAL: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients","volume":"9","author":"Hoen","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/ajkd.2002.30566_bib12","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.V971314","article-title":"Silent infection in clotted hemodialysis access grafts","volume":"9","author":"Ayus","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 4","key":"10.1053\/ajkd.2002.30566_bib13","doi-asserted-by":"crossref","first-page":"S152","DOI":"10.1016\/S0272-6386(98)70179-9","article-title":"Iron treatment: Impact of safety issues","volume":"32","author":"Fishbane","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.30566_bib14","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0272-6386(99)70163-0","article-title":"Erythropoietin and iron use in peritoneal dialysis patients: Report from the 1997 HCFA end-stage renal disease core indicators project","volume":"33","author":"Bailie","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.30566_bib15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1681\/ASN.V113530","article-title":"Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients","volume":"11","author":"Besarab","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/ajkd.2002.30566_bib16","series-title":"NKF-K\/DOQI Clinical Practice Guidelines for Anemia of Chronic Renal Failure","year":"2001"},{"key":"10.1053\/ajkd.2002.30566_bib17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/blood.V34.3.357.357","article-title":"Characteristics of iron dextran utilization in man","volume":"34","author":"Henderson","year":"1969","journal-title":"Blood"},{"key":"10.1053\/ajkd.2002.30566_bib18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/0272-6386(95)90649-5","article-title":"Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era","volume":"26","author":"Kalantar-Zadeh","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.30566_bib19","first-page":"524","article-title":"Impaired neutrophil defense against Yersinia enterocolitica in patients with iron overload who are undergoing dialysis","volume":"111","author":"Cantinieaux","year":"1988","journal-title":"J Lab Clin Med"},{"key":"10.1053\/ajkd.2002.30566_bib20","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/00005373-199608000-00030","article-title":"Iron and infection: New developments and their implications","volume":"41","author":"Ward","year":"1996","journal-title":"J Trauma"},{"key":"10.1053\/ajkd.2002.30566_bib21","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/bmj.296.6623.660","article-title":"Iron and infection","volume":"296","author":"Hershko","year":"1988","journal-title":"BMJ"},{"key":"10.1053\/ajkd.2002.30566_bib22","first-page":"377","article-title":"Risk factor for bacterial infections in chronic haemodialysis adult patients: A multicenter prospective survey","volume":"10","author":"Hoen","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/ajkd.2002.30566_bib23","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1046\/j.1523-1755.1999.00479.x","article-title":"Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia","volume":"55","author":"Tarng","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2002.30566_bib24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0272-6386(99)70103-4","article-title":"A study of parenteral iron regimens in hemodialysis patients","volume":"34","author":"Besarab","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.30566_bib25","first-page":"2070","article-title":"Importance of iron supply for erythropoietin therapy","volume":"10","author":"Sunder-Plassmann","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/ajkd.2002.30566_bib26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0272-6386(96)90462-X","article-title":"Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients","volume":"28","author":"St. Peter","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.30566_bib27","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0022-2143(98)90098-1","article-title":"Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: A double blind randomized trial","volume":"131","author":"Auerbach","year":"1998","journal-title":"J Lab Clin Med"},{"key":"10.1053\/ajkd.2002.30566_bib28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0272-6386(99)70183-6","article-title":"Sodium ferric gluconate complex in sucrose: Safer intravenous iron therapy than iron dextrans","volume":"33","author":"Faich","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.30566_bib29","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0272-6386(96)90463-1","article-title":"The safety of intravenous iron dextran in hemodialysis patients","volume":"28","author":"Fishbane","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.30566_bib30","series-title":"Ferrlecit package insert","year":"2001"},{"key":"10.1053\/ajkd.2002.30566_bib31","series-title":"Venofer package insert","year":"2001"},{"key":"10.1053\/ajkd.2002.30566_bib32","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0272-6386(01)80123-2","article-title":"Suspected iron dextran-related adverse drug events in hemodialysis patients","volume":"37","author":"Fletes","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2002.30566_bib33","first-page":"212","article-title":"The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period","volume":"55","author":"Silverberg","year":"2001","journal-title":"Clin Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638602119603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638602119603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T06:58:04Z","timestamp":1630911484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638602119603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,2]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2002,2]]}},"alternative-id":["S0272638602119603"],"URL":"https:\/\/doi.org\/10.1053\/ajkd.2002.30566","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2002,2]]}}}